Introduction
Drug hypersensitivity (DH) reactions are a modern and largely man made (iatrogenic) heterogeneous group of diseases, linked to the wide use of chemicals that are orally, parentally, or locally/topically applied. DH represents only a part of drug-related side effects. It is usually described as unpredictable and the clinical picture is not explained by the drug action or underlying disease: these unexpected clinical manifestations and the sometimes fulminant course make it an enigmatic area for clinicians and researchers. In addition, in DH, two highly variable systems meet: on one hand the endless number of novel small molecules, the majority chemically synthesized; and on the other, the highly variable immune system with > 10 11 different T-cell receptors (TCRs) and antibodies per individual, and a large number of human leukocyte antigens (HLA) molecules (> 9300) in the population (http://www.ebi.ac.uk/imgt/ hla/stats.html).
The predominant antigens for both T-cells/TCRs, as well as Bcells/immunoglobulins, are proteins; in particular structural or sequential epitopes [mostly 8w20-amino acid (AA) long peptide stretches] within or derived from larger proteins. The highly variable immune receptors are supposed to not interact with small molecules (< 1000 Da), as the high specificity of the immune receptors requires a certain size of its antigens to be recognized as antigen and be differentiated from other structures. If the antigen was very small, e.g. methanol (CH 3 OH), it could bind to many different regions within the protein receptor. However, even if it would fit into the receptor binding site, it would probably not provide enough surface interactions to cause signal transduction. A further checkpoint to exclude small molecules from activating the immune system is the need for cross-linking immune receptors to elicit an effector mechanism. Small molecules are too small to cross-link two adjacent immunoglobulins and their Fc-IgEreceptors; thus no cell signaling occurs.
In spite of these limitations, there are enough examples of drugs eliciting DH, drug-induced autoimmunity, and drug-induced immunodeficiency. Until recently, all these immune interactions were explained by the hapten features of the drug or drug metabolite (see below). However, during the last 15e20 years it has become clear that drugs have more possibilities to interact with the immune system than just by inducing an immune reaction by forming haptenecarrier complexes 1e10 : drugs are able to stimulate the innate immune system by binding to TLR (imiquimod), 1 drugs can bind to major histocompatibitlity complex (MHC) molecules and interfere with peptide loading onto MHCs (MHC loading enhancer, MLE), 2 which is similar to the altered peptide hypothesis, where drug binding to certain HLA alleles may affect the presentation of peptides presented by a certain allele. 3e5 In addition, drugs may also bind directly to a TCR and stimulate, in the presence of HLA/ peptide interactions, specific T-cells via TCR. 6, 7 The latter concepts, drug binding to the TCR or HLA with functional consequences, were originally described as pharmacological interactions of drugs with immune receptors (p-i concept). 8e10 In this review I will analyze briefly the hapten and prohapten concept, the initial findings leading to the p-i concept, the refinement of p-i (TCR) and p-i (HLA) concepts and extensions as elaborated during the last years. I compare immune stimulations by drug binding to TCR or HLA and their functional consequences and illustrate different possibilities of p-i using different drugs. Importantly, I indicate the possibility that peptide exchange is not a prerequisite of p-i (HLA) stimulations elicited by drugs, as drug binding to HLA per se already forms a highly immunogenic structure, which leads to strong T-cell activation in the presence of normal peptides (altered pHLA). Comparison of the hapten and p-i concepts is summarized in Table 1 .
The hapten concept
The limited interactions of small molecules with the immune system have been recognized by studying the (humoral) immune systemdand soon it became clear that there are ways to overcome it. The hapten concept goes back to the 1930s; a small molecule can gain antigenicity if it is bound to larger proteins 11, 12 : stable, covalent binding is required to modify the larger protein structure. Thereby the modified protein could be a foreign or an endogenously produced protein, to which tolerance has been developed. In both instances, the modified protein becomes a new antigen, as the stable hapten-binding modifies the protein. The modified protein (haptenecarrier complex) can under certain circumstances elicit Bcell reactions, antibody production and secretion anddafter processing to small peptides presented by MHCdT-cell reactions. The antibody specificity is often predominantly directed to the small hapten itself as even a small modification of the hapten can already abrogate the recognition of the whole haptenecarrier complex (Table 1) . 12 Haptens are chemicals that are chemically reactive and have a tendency to build covalent bonds to some AAs within a protein. For example, at least 13 lysine groups within the albumin molecule have been shown to bind piperacillin and were processed to different modified epitopes within the same protein. 13 For the immune system, accessible modifications may elicit antibody responses to these hapten-modified epitopes. If the antibodies react with the hapten bound to different sites on the same protein, crosslinking of the bound antibodies can occur. This requires a certain sterical distance between these hapten-modified epitopes, otherwise the rather large antibody molecule (their Fab part) would interfere with binding. If the antibody response is predominantly directed to the hapten and distant enough to allow two antibody bindings, cross-linking of the hapten-specific antibodies (including antibodies with the same specificity!) can occur by a single protein.
This may enhance and explain why hapten-specific IgE reactions are often fulminant and occasionally even fatal. Later, the work of Landsteiner et al showed that the delayed reaction to haptens (later shown to be T-cell mediated) is also very specific.
14 Proteins are processed and presented as small 8e20-AA long peptides by MHC-encoded molecules, which as proteins (HLA) appear on the cell surface. Thereby the 14e18 HLA molecules expressed per individual present different peptides (mostly 8e10 AA for HLA class I, w14e16 AA for HLA class II), which fit into the peptide binding groove of HLA-molecules. Further work by Weltzien et al demonstrated that the location of the hapten modification (in the middle or at the end of the 9-mer peptide) may influence the functional consequence of the evolving immune response, in particular cross-reactivity and autoimmunity. 15 It is important to realize that hapten-specific immune responses are complete immune responses, involving stimulation of antibodies and T-cells. Actually, if a drug is able to elicit both B-and Tcell immune responses, it is most likely to have hapten-like characteristics. Haptens are immunogenic and antigenic: their immunogenicity is linked to the ability to activate the innate immune system, mostly by binding to molecules that cause cell activation or damage. For quite a number of molecules it has been shown that haptenization leads to the activation of dendritic cells (DCs) in vitro, 16, 17 and this capacity of haptens is used to identify contact allergens by in vitro tools. The immunogenicity is supplemented by antigenicity, which is the provision of antigenic determinants for the specific immune receptors (B-and T-cell receptors). Not every hapten modification may result in an efficient immune response: if, for example, the hapten modifies a peptide sequence, which is not presented by the available HLA alleles, the hapten modification remains unnoticed by the immune system. If the hapten induced modification does not simultaneously activate the innate immune system it may remain ignored, as no efficient immunity will be developed.
An unexplained issue of the hapten (or prohapten) theory is the fact that hapten-formation is common for given drugs such as penicillin and happens in the majority of treated patients. IgG antibody formation to penicilloyl-determinants seems to be frequent. Why only a minority of patients develops an allergic, clinically symptomatic immune reaction is unclear.
The prohapten concept
Many drugs are not chemically reactive but are still able to elicit immune-mediated side effects. The prohapten hypothesis reconciles this phenomenon with the hapten hypothesis by stating that a chemically inert drug may become reactive upon metabolism. 18, 19 Sulfamethoxazole (SMX) is a prototype of such a prohapten. It is 21 Importantly, the metabolite may or may not be a hapten. If it not transformed to a hapten, it may stimulate the immune system like the parent compound (see allopurinol/oxypurinol).
The p-i concept
A completely different approach to view and analyze the interaction of small molecules with immune receptors is based on the pharmacological feature of drugs, meaning that small molecules have a tendency to interact with larger proteins. This feature is widely exploited in the design of drugs, which are often synthesized with the scope to fit into certain receptors or enzyme pockets and to block or stimulate them by noncovalent binding. Via this normal feature of drugs, they may also target immune receptors, whereby the enormous polymorphism of the highly variable immune receptors makes it rather likely that at least some of the TCRs, some of the antibodies, or of the HLA alleles bind a drug with a substantial affinity. While most of these interactions may remain functionally irrelevant, some data generated over recent years show that some of the drug bindings to immune receptors may lead to an unusual stimulation of the immune system ( Table 1 ).
Definition of p-i
The concept of drug interaction with immune receptors is called the p-i concept, meaning pharmacological interactions of drugs with immune receptors. According to the p-i concept, chemically inert drugs, unable to covalently bind to peptides or proteins, can nevertheless activate certain T-cells, if they fit with a sufficient affinity into some of the various T-cell receptors or MHC-molecules available. This reversible interaction is similar to the one of a ligand to its receptor.
8e10
One has to emphasize that it is a (noncovalent) drug binding to receptors based on van der Waals, electrostatic forces, or hydrogen bonds. The consequences of drug binding to either HLA or TCR might be quite distinct (see below). 22 As the reactive cells are immune cells, the functional consequences of this pharmacological action result in immune stimulations (or blockade). This does not mean, however, that the immune stimulation by binding a drug to immune receptors is based on an immune response, which is the result of a complex interplay of various cells and receptors. Indeed, the drug interaction with immune receptors is not a typical immune response or a consequence of recognition by specific immune receptors, as it occurs with protein antigens. The terminology recognition, as it is normally used to define the interaction of immune receptors with its antigen, is misleading in p-i. In p-i, binding of a drug and not of an antigen takes place; thus, the antigen is not an antigen and many controls of immune activations by an antigen are bypassed. In addition, the activation may have unusual features (see below). Actually, as the drug is designed for other purposes, the p-i based stimulation of immune receptors is a classical, unintended off-target effect of a drug. The p-i concept was developed using drug specific human T cells (T-cell clones; TCC). 6,23e26 It has not been used to explain B-cell stimulations or stimulations of Fc-receptor bearing cells by interacting with Fc-receptor bound antibodies. This is considered unlikely. At present it is unclear whether interactions of labile bound drugs to a serum protein (by multiple hydrogen bonds etc.) can form a complex stable enough to interact with antibodies and whether this results in an efficient signaling to B cells. It is also unclear whether such a labile drugeprotein complex can cross-link antibody molecules on Fc-receptors and thus cause cell activation. Nevertheless, one should be aware that positive immediate skin tests or basophil activation tests elicited by chemically inert, small drugs are documented and are not explained by the prevailing hapten concept.
A short history of the p-i concept
TCCs were first generated to penicillin G, 27e29 SMX, 6, 24 and lidocaine. 30 These TCCs were very specific, could be generated within weeks from patients with respective allergies and small modification of the drug abrogated reactivity. Analysis of SMX and lidocaine-reactive T cells made it clear that the stimulation of T cells by some drugs did not follow the rules described for classical protein antigens or haptenecarrier constructs: (1) Aldehyde-fixed antigen-presenting cells (APC; EpsteineBarr virus transformed autologous B-lymphoblastoid cell lines) were still able to activate TCCs, which specifically reacted with a drug (lidocaine, SMX). 23, 25, 31 Since fixed APCs are unable to take up the drug, it showed that no metabolism of the drug to a reactive compound nor processing of a drug modified protein antigen to a hapten-peptide was required to elicit TCC activation, as one would expect for hapten reactions or normal protein antigens. (2) Covalently bound haptens (such as penicillin G) are not removed from the drug (e.g. penicillin) pulsed APC by washing. In contrast, washing of APC incubated with lidocaine and SMX abrogates the reactivity to these drugs: this was interpreted as illustrating the lability of drug binding to its immune-receptors. 23, 30 This feature of the p-i concept made certain biochemical studies or studies with radioactive labeled drugs impossibledand remains one of the main reasons for skepticism of the p-i concept; recent data with abacavir reveal that this particular drug binds with sufficient affinity to the F-pocket in HLA-B*57:01 and is not washed away. 7, 32 However, this high affinity binding of a drug by noncovalent bonds is the exception and not the rule. (3) Calcium influx in TCCs happens within seconds (20e100 seconds) after the addition of the drug to the mixture of drug-specific TCCs and APCs. 25, 32 This time interval is too short to allow uptake, metabolism, processing of modified proteins to immunogenic peptides and presentation of modified peptides. (4) Blocking of drug metabolism or processing to peptides within APCs does not interfere with TCC stimulation; e.g. in the case of abacavir stimulation of TCCs, abacavir metabolizing enzymes are not expressed in immune cells and inhibition of metabolism or of proteasome in APCs does not affect TCC reactivity. 32 (5) Transfection of the TCR into hybridoma cells (not expressing human MHC) shows that: the drug specificity is due to a (transfected) specific TCR; both chains of the TCR are needed for signaling; and that interaction with HLA molecules presented on APC are required for full activation.
7,33
Functional analysis of TCC revealed some peculiar features 34, 35 : (1) Some CD4þ TCC are MHC class I restricted; some CD8-TCC are MHC class II restricted. 23, 26 (2) Quite a large proportion of drug-specific
TCCs simultaneously express CD4 and CD8; while an effect of cell culture cannot be ruled out on the generation of these doublepositive T cells, the frequency of such reactions is substantially higher in drug compared to peptide specific cultures/TCCs. In addition to SMX and lidocaine, carbamazepine (CBZ)-and lamotrigine-specific TCCs were often double positive. 36 These data prompted the development of the p-i concept 8e10 to explain these puzzling features.
One typical clinical feature of p-i is that the clinical effect is restricted to T cell reactions: there are no descriptions of anaphylaxis to classical p-i reacting drugs such as CBZ, phenytoin, and lamotrigine, although these drugs have obviously a high potential to stimulate the immune system. It is doubtful whether B cells are activated by these drugs, and the activation of the innate immune system and activation of DCs is also often questionable; if it happens, it might occur as a consequence of prior, direct drug-induced T-cell stimulation. Other drugs such as SMX may act mainly via p-i, but may occasionally also elicit anaphylaxis, as hapten responses are also occurring (to SMX-NO).
Direct p-i (p-i TCR)
Full T-cell activation by the drug (measured by immediate Ca 2þ influx into specific T-cells, cytokine synthesis and proliferation) requires the interaction of the TCRs with MHC (documented for MHC class II) on APCs. This was proven by testing hybridoma cells of mouse origin (devoid of human MHC), which were transfected with drug (SMX or quinolone) specific TCR: they did not mount a full response (IL-2 secretion) to addition of the drug. Only if APCs with human MHC were provided, did they react. 7, 33 The data also raise the question of whether the drug binds first to the MHC molecule (p-i HLA), modifying its structure and thus leading to specific T-cell activation (¼ indirect p-i), or whether the drug binds primarily to specific TCRs, rendering the MHC interaction a necessary, but only supplementing signal (p-i TCR, direct p-i). Initial data suggest that the interaction of the drug happens first with the TCR, since in SMX and lidocaine models the MHC-bound peptide could be exchanged or removed without affecting CD4 þ T-cell activation. 35, 39 Moreover, some TCCs react to the drug even in the presence of allogeneic MHC molecules, indicating that no strict HLA restriction for SMX or lidocaine presentation exists. 31, 35 Indeed, a recent study showed that in certain SMX specific TCCs, other, structurally related sulfanilamides may block the stimulation of SMX. 40 Docking studies have revealed that these blocking sulfanilamides bind to the same site as SMX (CDR3), but without signaling. Other TCRs/TCCs are also reactive with SMX, but the cross-reactivity with sulfanilamides differs by: (1) 
Indirect p-i, (p-i HLA)
A decisive step forward in understanding severe, T-cell-mediated DH reactions was the description of a strikingly high HLA-B-allele association 44e46 for certain severe DH reactions. The HLA-allele associations are extremely high, with a negative predictive value close to 100%; this is linked to the reaction to a particular drug, and mostly linked to severe reactions. The frequency of the involved allele in the population is important for linkage associations. 47 The strong association raises the question of whether this linkage is due to the allele itself or the presented peptide. Elution of the peptide shows clearly that the peptides are not modified, neither in CBZ nor in abacavir hypersensitivity reactions.
3e5, 42 In the case of HLA-B*57:01 linked abacavir hypersensitivity 4,48 the binding of abacavir to the F-pocket can be shown by crystallography. 4 A similar binding cleft can be identified for CBZ, which binds to HLA-B*15:02, an allele rather common in southeast Asia and probably responsible for the high occurrence of SJS/TEN due to CBZ in these regions. 4, 45 Thus, p-i (HLA) can be verified by various means and for different drugs.
Altered peptide model
What is the consequence of drug binding to HLA? In principle, two possibilities exist: the drug may alter the peptide presented (altered peptide repertoire), 3e5 or the drug may, by binding to HLA, alter the whole immunogenic conformation (altered HLA). Recent studies on abacavir hypersensitivity have not only shown that abacavir can bind by noncovalent bonds in the F-pocket of the HLA-B*57:01 groove, but also that this binding can even modify the peptide binding properties of HLA-B*57:01. 3e5 These in vitro studies have been done using rather high concentrations of abacavir (100 mg/mL). Three different groups showed that in the presence of abacavir more peptides harboring a small aliphatic anchor residue at the C-term are loaded, leading to an altered peptide repertoire. About 20% of eluted peptides were altered peptides. These studies also suggest that not abacavir but an altered peptide is the antigen in abacavir hypersensitivitydthus postulating a possible link between DH and autoimmunity. It should be noted that the concept of altered peptide presentation has already been approached from a different viewpoint. In the search to optimize MHC peptide presentation and to improve vaccination efficacy, Dickhaut et al described so-called MLEs, which are small catalytic compounds able to open up the MHC binding site by triggering ligand-release and stabilizing the receptive state of MHC class II molecules. 2 One such MLE is adamantane ethanol, but abacavir may have a similar ability on MHC I (B*57:01).
Altered pHLA model
A separate extensive analysis of many abacavir reactive TCC challenges the altered peptide concept and came to a the conclusion that peptide exchange is not necessary for immunogenicity (32) . Altering the HLA-(self) allele without modifying the peptide sequence is sufficient for immunogenicity, as drug binding alters the whole conformation of the HLA-peptide complex (pHLA) as seen from the TCR and make the self-allele plus self-peptide antigenic for T-cells. The crucial experiment is shown in Figure 1 : abacavir binds to B*57:01 with high affinity and resists washing of abacavir incubated cells. When APC are pulsed with abacavir overnight, it is internalized and loaded in the endoplasmic reticulum (ER) on HLA B*57:01 (¼ abacavir pulsing). Ca 2þ influx assays reveal that all abacavir-induced TCCs reacts to these abacavir pulsed APCs, and some of the reactive TCC required pulsing with only small amounts of abacavir (1 or 10 ng/mL) to react to the pulsed APC. Some TCCs react not only after pulsing, which allows abacavir loading onto empty HLA-B*57:01 in the ER, but also quasi-immediately (within 60e120 seconds), when abacavir is presented on the surface. Full reactivity to surface loaded HLA requires rather high concentrations (1 or 10 mg/mL), probably because loading on surfaceexpressed HLA-B*57:01 is hampered by the already presented peptides. Thus only TCC, which carried TCR with a high avidity for the HLAeabacavirepeptide complex, showed a reaction. The data show that: (1) reactivity of abacavir-induced TCCs to surface abacavir is dependent on the dose of abacavir and density of HLA-B*57:01 32 ; (2) abacavir can bind to and modify HLA-B*57:01 on the surface (at 1e10 mg/mL) or in the ER (with 1000-fold lower concentrations); and (3) that an altered peptide is not necessary to induce abacavir reactivity. It is unclear whether the TCCs react to the same or different peptides, when abacavir loading takes place in the ER or on the surface. The finding that a normal tolerogenic peptide may become immunogenic, just by altering the presenting (self) allele by the rather strong drug (abacavir) binding to B*57:01, has major implications for understanding DH. It needs to be verified by other drugs. It candin analogy to altered peptide modeldbe named the altered pHLA model (Figure 1 ).
Open questions for p-i
The p-i concept is an nonimmunological approach to an immunological problem, namely how a small molecule interacts with the immune system. It postulates a pharmacological interaction without the multiple checkpoints typical for immune reactions (activation of DCs, costimulation). This feature of p-i could explain the self-destructive nature of some DH reactions. By contrast, the possibilities of the immune system to react are limited to immune reactions and while it appears bizarre, they are partly similar to normal immune stimulations and have some similarities to virus stimulations, or occasionally to graft-versus-host or superantigen stimulations. Differentiating p-i TCR or p-i HLA also raises several points (see below).
p-i stimulation of preactivated cells
Already by conceiving the p-i concept it was enigmatic how a small molecule might stimulate T cells. This refers mainly to p-i TCR stimulations, for which initially more data have been accumulated than for the later elaborated p-i HLA stimulations. Actually, it has been speculated that only effector/memory cells may react to the minor signal as drug binding to TCR (p-i TCR), since memory T cells have a substantially lower threshold for activation than naïve T cells. This threshold of T-cell activation might be low in the skin, 49, 50 where sentinel T cells show indeed a lower threshold of activation than resting circulating T cells. 50 Also a concomitantly occurring massive immune stimulation of T cells, as it occurs during generalized herpes or human immunodeficiency virus infections, or during exacerbations of autoimmune diseases, may be a cofactor for lowering the threshold of T-cell activation by drugs; such immune processes go along with high cytokine levels and an increased expression of MHC-and costimulatory molecules on APC and other cells. 51 Consequently, T cells are already preactivated by the immune stimulation and might be more ready to react to a minor signal such as binding of a drug to its TCR. This would explain the high occurrence of drug hypersensitivities in these diseases. However, experimental data supporting these clinical observations are still missing.
Multiple DH
About 10% of patients with severe drug allergies develop a second drug allergy; as recently shown, patients with multiple DH carry in their blood T-cells with a particular phenotype, similar to herpesvirus stimulated T-cells. 52 However, these individuals were negative for human herpesvirus-6, EpsteineBarr virus, and cytomegalovirus infections. This peculiar cell fraction contains the precursor T cells for different drugs, while the normal cell fraction does not contain these precursor cells. This finding shows that some preactivation may play a role; and that a neglected risk factor for DH is the existence of a DHdeither ongoing or in remission.
Costimulation by metabolites
While the p-i concept has been documented for many drugs (SMX, lidocaine, lamotrigine, CBZ, p-phenylenediamine, quinolones, radio contrast media, abacavir, flucloxacillin, and more) 6,7,23,25,32,36,37,53e 55 in some drug reactions, the metabolites of the parent compound are often also implicated in DH. Cloning suggests that some of these TCCs/TCRs are reactive via p-i not only to the parent compound, but possibly also to a metabolite. 56 Some of the implicated metabolites might be chemically reactive and cause hapten-like stimulations. Thus, immune reactions might evolve via p-i stimulations and hapten simultaneously. The reaction to a hapten raises the question of whether the hapten-characteristic of a drug, with its immunostimulatory consequences on innate immunity, might be a cofactor for some p-i mediated stimulations. 19 
Differences and similarities of p-i stimulations by various drugs
In addition to maculopapular exanthems, drug rash with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis, SJS/TEN, and some other severe hypersensitivity syndromes were described for drugs that stimulate in vitro via the p-i concept. Often positive patch tests or delayed Figure 1 (A) It is assumed that abacavir-induced T-cell clones (TCCs) react with a peptide and not abacavir itself, 4 as abacavir binds to the F-pocket with no direct access to the T-cell receptor for antigen (TCR). However, the doseeresponse curve is at first sight suggestive of direct abacavir reactivity. 32 How can one explain this? All abacavir-induced TCCs react to antigen-presenting cells (APCs), which were pulsed with abacavir over night. A fraction of these TCCs carry TCRs that have enough affinity for the human leukocyte antigens (HLA)-appearing intradermal reactions and positive lymphocyte transformation tests could be found. The reactivity in skin or in vitro tests often appears very similar between p-i or hapten-stimulated drugs and cannot be differentiated by the clinical picture alone. The clinical symptoms by the p-i drugs may appear more rapidly and some severe reactions such as SJS/TEN, DRESS, or hypersensitivity syndromes are clearly p-i related. In addition, the concentration of the drug isdlike in other pharmacological reactionsddecisive for the clinic in p-i reactions. It is not infrequent that DRESS symptoms arise after increasing the dose. A summary of the best defined p-i acting drugs and their peculiarities is given in Table 2 . In some, the affinity of drug binding to HLA may be crucial (illustrated by abacavir), other drugs may be presented by various HLA-alleles but with different affinity and severity (CBZ, allopurinol), in B*58:01 associated allopurinol hypersensitivity the metabolism to oxypurinol is required, 57 in SMX and CBZ, the binding to TCR is important, and in flucloxacillin not the hapten, but the p-i stimulation may be decisive for liver damage. Altogether, the p-i stimulating drugs vary considerably (Table 3) . Abacavir (ABC) binding to B*57:01 differs from other drug binding by its high affinity to the HLA-B*57:01. Abacavir is not washed away by incubating it with B*57:01þ cells. It is very selective for abacavir, but not for similar nucleoside analogues. B*57:01 has a high positive predictive value of 47.6% for abacavir hypersensitivity manifestations), if the patient is patch test positive. This high association of B*57:01 and hypersensitivity manifestations might be related to the high affinity interaction of abacavir with B*57:01. Abacavir reactivity may appear as early as 1e3 days after treatment started, and is detected after 2 weeks culture in every B*57:01þ individual, indicating a rather high precursor frequency. 58 No other allele, even B*58:01, has been linked to abacavir hypersensitivity, where the difference between B*57:01 and B*58:01 is only one AA in the peptide binding groove.
abacavir/peptide complex, if abacavir is added on the surface to cells; these can react immediately (60e100 seconds) to APCs plus abacavir. Their reactivity is dependent on abacavir dose and HLA concentration. However, all abacavir induced TCCs, including the high affinity TCC, also react to abacavir pulsed APCs, even when using 1000-fold lower abacavir concentrations (1 ng/mL). (Figure reproduced from reference 32, with permission.) (B) Loading of abacavir onto HLA-B*57:01 is easier in the endoplasmic reticulum (ER), when HLA molecules were not yet loaded with peptides-p. If abacavir is added to APCs on the surface, the HLA-B*57:01 are already filled with peptides, which competed and partially blocks abacavir access to the F-pocket. Loading on the surface is thus suboptimal and only high avidity TCCs that are sufficiently stimulated by a few HLAeabacavirepeptide complexes react. The immediate reactivity of the abacavir induced TCC is not compatible with a reactivity to altered peptide, 3e5 as the time did not allow peptide exchange. Thus abacavirinduced TCCs react either with abacavir itself (unlikely) or in the presence of abacavir with normal peptide as well (pHLA). Simple modification of HLA by abacavir binding (without peptide exchange) induces reactivity: this model is called altered pHLA model. As the TCC reacts with normal peptide on abacavir altered HLA, the role of altered peptides, described for very high concentrations only, is unclear. The normal peptide was presented by surface-loaded or ER-loaded abacavireHLA complexes. Whether the TCC do always react to the same, endogenous peptide or to different peptides, is at present unclear. It is possible that different peptides were recognized by the same TCCs, which is not uncommon in alloreactive T cells (polyspecificity). The interaction with B*15:02 seems to be rather strong, but has less affinity than the one with abacavir. Docking studies have placed CBZ in the middle of the peptide binding groove, at the secondary anchor residue. It can also induce presentation of altered peptides, which was observed in about 15% of peptides presented (4). Thus, it might, like abacavir, actually induce a peptide response. The T-cell response to CBZ in B*15:02þ individuals seems to be oligoclonal. 43 It has been reported that only if a certain TCRclonotype is available, does a strong cytotoxic immune response to CBZ develop. This clonotype (VB-11-ISGSY) is also present in healthy individuals; such cells could be primed to develop into cytotoxic T-cells by CBZ exposure (59) . The example illustrates nicely that some drugs may develop immune stimulations by binding to HLA and TCR.
McCluskey et al has also postulated a possible role of altered peptide presentation in CBZ-induced B*15:02-linked hypersensitivity reactions. 4 However, no data demonstrating a T-cell reaction to the altered peptide have been obtained so far. Thus, while the possibility of altered peptide presentation is well documented (at least for abacavir), actual relevance and the in vivo role of altered peptide presentation is not yet well documented. Flucloxacillin is a penicillin derivative and actually a typical hapten. Flucloxacillin binds covalently to selective lysine residues in albumin in a time-dependent manner. 13 57 Dose seems to be a crucial factor in developing these sometimes severe side effects. The immune response is due to p-i HLA, and is mainly directed to oxypurinol. 57 SMX is a drug that causes a variety of hypersensitivity reactions, which are not known to be HLA-allele linked. It is a typical prohapten, and some side effects appear to be linked to hapten feature of this drug (SMX-NO), while in other reactions like the DRESS syndrome by SMX or sulfapyridine (the relevant component of sulfasalazine) hypersensitivity reactions are caused by direct binding to TCRs. 6, 7, 23, 26, 40, 41 Thus, these reactions are p-I TCR mediated; the binding site of SMX (and other sulfanilamides) in two SMX-specific TCC has been identified by blocking and docking studies on the CDR2 and CDR3 regions of the TCR and by molecular dynamics modeling. 40, 41 Binding may result in signaling (with Ca   2þ influx and proliferation, if interaction with HLA is possible). Surprisingly, the T-cell reactions are often polyclonal at the start, but SMX, and other drugs (e.g. iodixanol) may occasionally cause an oligoclonal or even monoclonal T-cell outgrowth. 54 
Conclusion
Taken together, the p-i concept suggests that some drug allergies are pharmacological off-target reactions and not true allergies. Drugs are able to interfere with the human immune system not only as an antigen (namely as hapten coupled to a carrier molecule), but also by pharmaceutical means, namely by drug acting on (immune) receptors. The dogma that small chemicals are not full antigens is still valid and must not be refused, but DH-like reactions can occur also by simple pharmacological means, namely by stimulation of drug binding to (immune) receptors such as HLA or TCR. From a general perspective, DH reactions and the underlying p-i concept demonstrate certain limitations of modern medicine: DH is, like graft-versus-host diseases or transplant rejections, an unusual (or, better, unnatural) way of immune stimulation, which was not foreseen in the natural evolution of the immune system. The immune system was neither prepared for the wide use of chemicals/drugs, nor was the immune system prepared that humans will transplant organs. In a certain sense, DH is, like transplantation medicine, the toll we have to pay for some progress made in medicine. However, these limitations may be overcome by a better understanding of the molecular mechanism of DH. Indeed, as recently shown for abacavir and carbamazepine hypersensitivity, the use of HLA-B*57:01 or -B*15:02 typing in risk populations can drastically reduce the incidence of new hypersensitivity reactions. 61, 62 It thus nicely illustrates how understanding leads to a better clinical practice, which we owe our patients particularly in an iatrogenic disease such as DH.
